Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPOTASSIUM CITRATE (potassium citrate) by ANI Pharmaceuticals is extended-release tablets are given orally, the metabolism of absorbed citrate produces an alkaline load. Approved for renal tubular acidosis [see clinical studies ()], hypocitraturic calcium oxalate nephrolithiasis [see clinical studies ()], uric acid lithiasis with and 1 more indications. First approved in 2020.
Drug data last refreshed 18h ago
extended-release tablets are given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium…
Worked on POTASSIUM CITRATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo